BioXcel Therapeutics, Inc. (BTAI) › Operating Cash FlowBioXcel Therapeutics, Inc. (BTAI) — Operating Cash FlowAnnual figures by period end, from SEC filings.2017-12-31: -$2.20M2018-12-31: -$13.51M2019-12-31: -$27.10M2020-12-31: -$66.35M2021-12-31: -$82.15M2022-12-31: -$135.34M2023-12-31: -$155.01M2024-12-31: -$72.03M2025-12-31: -$57.62M-$57.62M2017-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31-$57.62M—2026-03-27From 2025-01-012024-12-31-$72.03M—2026-03-27From 2024-01-012023-12-31-$155.01M—2025-03-28From 2023-01-012022-12-31-$135.34M—2024-03-22From 2022-01-012021-12-31-$82.15M—2023-03-16From 2021-01-012020-12-31-$66.35M—2022-03-11From 2020-01-012019-12-31-$27.10M—2021-03-12From 2019-01-012018-12-31-$13.51M—2020-03-09From 2018-01-012017-12-31-$2.20M—2019-03-12From 2017-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)